It was originally developed as a potential treatment for pandemic
influenza strains, including lethal ones such as A(H1N1)pdm09, A(H3N2) and
H5N1, and most of the trials conducted focused on anti-influenza activity. However, riamilovir has also been found to have antiviral activity against a number of other RNA viruses including COVID-19,
tick-borne encephalitis virus, and is also being investigated for potential application against a lethal influenza infection and secondary bacterial pneumonia following influenza,
Lassa fever and
Ebola virus disease. Riamilovir has passed clinical trials and has shown antiviral activity against ARVI. In 2020, testing of riamilovir was started against
SARS-CoV-2 in Russia, China, and South Africa. Randomized, double-blind, multicenter trial published in 2024 show that Riamilovir has demonstrated efficacy in both treating and preventing COVID-19. In August 2014, the Ministry of Health of Russia issued a registration certificate for riamilovir (Triazavirin). The active substance of the drug triazavirin is a new active molecule, and can be dispensed by prescription. The production of riamilovir is carried out at a modern pharmaceutical enterprise LLC "Plant Medsintez". The registration procedure for riamilovir has begun in the Republic of South Africa. ==See also==